Quest Magazine

First Drug for Duchenne Muscular Dystrophy Gets 'Conditional Approval' in Europe

DMD: Ataluren Receives Conditional Approval in Europe

Update (Oct. 24, 2014): Enrollment for the phase 3 trial of ataluren is complete, with results expected in the second half of 2015. See the PTC press release of Sept. 9, 2014.

=====================================================================================

original story:

PTC Therapeutics Receives Conditional Approval in the European Union for Translarna™ for the treatment of Nonsense Mutation Duchenne Muscular Dystrophy

ISIS-SMNRx to Be Tested in Phase 3 Trial in Infants With SMA

California-based Isis Pharmaceuticals has announced the opening of a phase 3 clinical trial of its experimental drug ISIS-SMNRx in infants with spinal muscular atrophy (SMA), a muscle-weakening disease that results from loss of nerve cells in the spinal cord.

Safeway Inc. and The Safeway Foundation Fundraising Campaign to Support Programs for People with Disabilities

Jiffy Lube® Supports Fight Against Muscle Disease With Third Annual MUSCLE UP® Campaign

Fire Fighters and MDA Celebrate “60 Years Strong”

DMD: ReveraGen Drug Will Move to Human Testing

ReveraGen BioPharma, based in Silver Spring, Md., is moving ahead with a phase 1 trial of an experimental compound in development to treat Duchenne muscular dystrophy (DMD), made possible by a $2 million grant from U.S.-based MDA and three United Kingdom-based DMD organizations.

International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

DMD: Eteplirsen Data Still Encouraging at 144 Weeks

Walking ability and respiratory function in boys with Duchenne muscular dystrophy (DMD) show continued benefit from eteplirsen at 144 weeks (almost three years), the drug's developer announced today. In addition, the intravenously infused drug was well tolerated, with no serious treatment-related adverse events seen.

Pages